钟南山称白云山复方板蓝根对新冠病毒有效

亲爱的英语 阅读:39827 2020-10-17 12:06:41

来源:界面新闻

记者|梅岭

钟南山团队在近期表示,体外研究发现白云山复方板蓝根对新冠病毒有效。受此消息影响,白云山(00874.HK)及白云山(600332.SH)10月16日早盘股价出现大幅拉升,一度触及涨停,截止当日上午收盘,白云山(600332.SH)上涨8.40%,报33.68元/股,港股白云山大涨12.76%,报21.65港元/股。

白云山复方板蓝根颗粒对新冠病毒有效的消息,源自10月13日“粤澳呼吸道病原体新药联合研究中心”第四次理事会白云山板蓝根澳门转化研讨会暨合作签约仪式。

根据公开报道,签约仪式后,白云山板蓝根、白云山复方板蓝根科研成果计划在澳门产业化,成为广药集团澳门国际总部成立后首个落地项目。该项目将由钟南山担任首席科学家领导团队开展白云山板蓝根研究成果的快速、高效转化。

钟南山院士在报告中提及。新冠疫情发生以来,研究团队十分重视“南药”抗新冠病毒的研究,结合临床实践的有益经验,与广药集团合作对旗下10个企业的16个已上市中成药开展了抗新型冠状病毒的体外药效筛选,发现了白云山复方板蓝根颗粒具有体外抑制药效。

根据2020年半年报,白云山报告期内实现营收304.7亿元,同比下滑8.61%,归属于上市公司股东净利润为17.64亿元,同比下滑30.75%。

上半年业绩下滑主要因受新冠疫情期间医院就诊患者数量减少、物流配送受到限制、药品终端需求下降等因素影响,大南药板块的医院销售品种及相关产品的销量呈现不同程度的下滑,大商业板块的医药配送业务也受到一定影响。

此外,王老吉凉茶市场需求受压,春节档销售受疫情影响较大,及王老吉大健康公司收到政府补助同比减少也是上半年公司业绩下滑的原因。

10月8日,白云山公告表示,公司董事会已审议并通过拟拆分子公司广州医药首次公开发行H股的议案。2019年和2020年上半年,广州医药分别实现营收411.3亿元、196.62亿元,实现净利润3.4亿元、1.71亿元,是白云山的重要利润来源之一。

Reporter Meiling

Zhong Nanshan team recently said that in vitro studies have found that Baiyunshan Compound Radix Isatidis is effective against new coronavirus. Affected by the news, the stock prices of Baiyunshan (00874. HK) and Baiyunshan (600332. SH) rose sharply in the morning trading on October 16, and once touched the trading limit. As of the morning closing of the same day, Baiyunshan (600332. SH) rose 8.40% to 33.68 yuan / share, and Hong Kong stock Baiyunshan rose 12.76% to HK $21.65/share.

The news that Baiyunshan compound Banlangen Granules are effective against new coronavirus originated from the fourth council of "Guangdong Macao Joint Research Center for respiratory pathogens new drugs" on October 13.

According to public reports, after the signing ceremony, the scientific research achievements of Baiyunshan Banlangen and Baiyunshan compound Banlangen are planned to be industrialized in Macao, becoming the first landing project after the establishment of the Macao International Headquarters of Guangzhou Pharmaceutical Group. Zhong Nanshan will act as the chief scientist of the project and lead the team to carry out the rapid and efficient transformation of the research results of Isatis indigotica in Baiyun Mountain.

Academician Zhong Nanshan mentioned in the report. Since the outbreak of novel coronavirus, the research team has attached great importance to the research of the anti crown virus of South medicine. Combined with the beneficial experience of clinical practice, we have worked with Guangyao group to carry out in vitro screening of the new type of coronavirus in 16 Chinese patent medicines of 10 enterprises. We found that Fufang Banlangen Keli Baiyun Mountain had the inhibitory effect in vitro.

According to the semi annual report of 2020, during the reporting period, Baiyunshan achieved revenue of 30.47 billion yuan, a year-on-year decrease of 8.61%, and the net profit attributable to shareholders of listed companies was 1.764 billion yuan, a year-on-year decrease of 30.75%.

The decline of performance in the first half of the year was mainly due to the decrease in the number of patients in the hospital during the period of Xinguan epidemic, the limitation of logistics and distribution, and the decline of drug terminal demand. The sales volume of hospital sales varieties and related products in the Da Nan pharmaceutical plate decreased to varying degrees, and the pharmaceutical distribution business of the large commercial plate was also affected.

In addition, the market demand of Wanglaoji herbal tea was under pressure, the sales of Spring Festival stalls were greatly affected by the epidemic situation, and the decrease of government subsidies received by Wanglaoji health company on a year-on-year basis were also the reasons for the company's performance decline in the first half of the year.

On October 8, Baiyunshan announced that the company's board of directors had considered and approved the proposal to dismantle Guangzhou Pharmaceutical's initial public offering of H shares. In 2019 and the first half of 2020, the revenue of Guangzhou Pharmaceutical is 41.13 billion yuan and 19.662 billion yuan respectively, and the net profit is 340 million yuan and 171 million yuan, which is one of the important profit sources of Baiyunshan.

声明

声明:转载此文是出于传递更多信息之目的。若有来源标注错误或侵犯了您的合法权益,请作者持权属证明与本网联系,我们将及时更正、删除,谢谢。

发表评论